Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL7917031 | 0.93 | — | — | |
| Acrylic Acid SCHEMBL11765048 | 0.89 | — | — | |
| Acrylic Acid SCHEMBL29091720 | 0.89 | — | — | |
| Acrylic Acid SCHEMBL673030 | 0.89 | — | — | |
| Acrylic Acid SCHEMBL30550947 | 0.89 | LMNA (0.91) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| SCHEMBL43941 | 0.89 | — | — | |
| SCHEMBL26040091 | 0.89 | — | — | |
| SCHEMBL9357930 | 0.89 | LMNA (0.50) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL29142217 | 0.86 | LMNA (0.71) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL3670955 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| EP-3844151-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11267812-B2 | KRAS G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3880208-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210230170-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| EP-3844151-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3458445-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10633381-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2020047192-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-03-05 | — | — | WO | disclosed |
| CN-110483731-A | A kind of pH sensitivity polyurethane hydrogel and its preparation method and application | UNIV SHANDONG | 2019-11-22 | — | — | CN | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
| US-20190144444-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-05-16 | — | — | US | disclosed |
| EP-3458445-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10125134-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2018-11-13 | — | — | US | disclosed |
| CN-108559048-A | A kind of pH sensitive biodegradable polyurethane urea material and preparation method thereof | 山东师范大学 | 2018-09-21 | — | — | CN | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144444-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-10633381-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-11267812-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-10125134-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-20200308170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
| US-20210230170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2914/4885ALOX15 3586/4885HSD17B10 3793/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 2991/4885ALOX15 3532/4885HSD17B10 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.